FDA clears Nycomed contrast injector

Article

Nycomed Amersham may be planning to bring a CT contrast injector system to market. Food and Drug Administration records indicate that the agency on Feb. 19 granted 510(k) clearance to the Anglo-Norwegian company for a device called Premica, listed as a

Nycomed Amersham may be planning to bring a CT contrast injector system to market. Food and Drug Administration records indicate that the agency on Feb. 19 granted 510(k) clearance to the Anglo-Norwegian company for a device called Premica, listed as a CT contrast media delivery system.

If Nycomed Amersham does bring such a product to market, it would compete with contrast injectors from companies owned by two of Nycomed's competitors in the contrast business, Schering and Mallinckrodt. Schering owns Medrad of Indianola, PA, while Mallinckrodt owns St. Louis-based Liebel-Flarsheim. Nycomed does not currently market a contrast delivery system.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.